Tapentadol in cancer pain management: a prospective open-label study.

  title={Tapentadol in cancer pain management: a prospective open-label study.},
  author={Sebastiano L Mercadante and G. Porzio and P. Mart{\'i}nez Ferrera and Federica Aielli and Claudio Adile and Corrado Ficorella and Antonello Giarratano and Alessandra Casuccio},
  journal={Current medical research and opinion},
  volume={28 11},
OBJECTIVES The aim of this prospective, open-label study was to evaluate the efficacy and tolerability of tapentadol (TP) in the management of cancer pain. METHODS A 4 weeks' prospective study was carried out in 50 opioid-naive cancer patients with moderate-severe pain. Each patient initially received twice-daily doses of slow-release TP 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity, on the basis of the clinical response. The following parameters were… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
25 Citations
22 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 25 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

Tapentadol HCl. Drugs Future

  • TM Tzschentke, J De Vry, R Terlinden
  • 2012
1 Excerpt

Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain

  • W Schoder, J De Vry, TM Tzeschentke
  • Eur J Pain 2010;14:814-21
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…